JP4981453B2 - シトクロムｃタンパク質及びアッセイ - Google Patents

シトクロムｃタンパク質及びアッセイ Download PDF

Info

Publication number: JP4981453B2
Authority: JP; Japan
Prior art keywords: cell; construct; cytochrome; promoter; agent
Prior art date: 2003-12-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

JP2006544552A

Other languages

English (en)

Japanese (ja)

Other versions

JP2008502316A (ja

Inventor

スタッブス，サイモン・ローレンス・ジョン

フランシス，マイケル・ジョン

クッシング，エイドリアン

イスマイル，ラマン・アジズ

Original Assignee

ジーイー・ヘルスケア・ユーケイ・リミテッド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-19

Filing date

2004-12-17

Publication date

2012-07-18

2004-12-17 Application filed by ジーイー・ヘルスケア・ユーケイ・リミテッド filed Critical ジーイー・ヘルスケア・ユーケイ・リミテッド

2008-01-31 Publication of JP2008502316A publication Critical patent/JP2008502316A/ja

2012-07-18 Application granted granted Critical

2012-07-18 Publication of JP4981453B2 publication Critical patent/JP4981453B2/ja

2024-12-17 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

108010075031 Cytochromes c Proteins 0.000 title claims abstract description 74
102100030497 Cytochrome c Human genes 0.000 title claims abstract description 69
238000003556 assay Methods 0.000 title abstract description 10
210000004027 cell Anatomy 0.000 claims abstract description 138
230000006907 apoptotic process Effects 0.000 claims abstract description 46
150000007523 nucleic acids Chemical class 0.000 claims abstract description 29
108020001507 fusion proteins Proteins 0.000 claims abstract description 23
102000037865 fusion proteins Human genes 0.000 claims abstract description 23
210000003470 mitochondria Anatomy 0.000 claims abstract description 20
108020004707 nucleic acids Proteins 0.000 claims abstract description 20
102000039446 nucleic acids Human genes 0.000 claims abstract description 20
108010052832 Cytochromes Proteins 0.000 claims abstract description 19
102000018832 Cytochromes Human genes 0.000 claims abstract description 19
239000005090 green fluorescent protein Substances 0.000 claims description 48
239000003795 chemical substances by application Substances 0.000 claims description 40
108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 26
102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 26
230000004927 fusion Effects 0.000 claims description 23
238000000034 method Methods 0.000 claims description 23
230000000694 effects Effects 0.000 claims description 16
239000013598 vector Substances 0.000 claims description 15
102000034287 fluorescent proteins Human genes 0.000 claims description 13
108091006047 fluorescent proteins Proteins 0.000 claims description 13
230000025915 regulation of apoptotic process Effects 0.000 claims description 12
238000006467 substitution reaction Methods 0.000 claims description 12
238000012258 culturing Methods 0.000 claims description 8
230000001105 regulatory effect Effects 0.000 claims description 8
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims description 7
241000271566 Aves Species 0.000 claims description 6
108010048367 enhanced green fluorescent protein Proteins 0.000 claims description 6
239000002773 nucleotide Substances 0.000 claims description 6
125000003729 nucleotide group Chemical group 0.000 claims description 6
241000579895 Chlorostilbon Species 0.000 claims description 5
101000726355 Homo sapiens Cytochrome c Proteins 0.000 claims description 5
229910052876 emerald Inorganic materials 0.000 claims description 5
239000010976 emerald Substances 0.000 claims description 5
210000004962 mammalian cell Anatomy 0.000 claims description 5
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
108090000848 Ubiquitin Proteins 0.000 claims description 4
102000044159 Ubiquitin Human genes 0.000 claims description 4
108091005948 blue fluorescent proteins Proteins 0.000 claims description 4
108010082025 cyan fluorescent protein Proteins 0.000 claims description 4
210000005260 human cell Anatomy 0.000 claims description 4
108010054624 red fluorescent protein Proteins 0.000 claims description 4
239000013603 viral vector Substances 0.000 claims description 4
108091005957 yellow fluorescent proteins Proteins 0.000 claims description 4
102220566687 GDNF family receptor alpha-1_F64L_mutation Human genes 0.000 claims description 3
230000008859 change Effects 0.000 claims description 3
230000035945 sensitivity Effects 0.000 claims description 3
230000003612 virological effect Effects 0.000 claims description 3
241000251468 Actinopterygii Species 0.000 claims description 2
241000701822 Bovine papillomavirus Species 0.000 claims description 2
102220469884 CTP synthase 1_K73Q_mutation Human genes 0.000 claims description 2
241000701022 Cytomegalovirus Species 0.000 claims description 2
241000702421 Dependoparvovirus Species 0.000 claims description 2
241000196324 Embryophyta Species 0.000 claims description 2
241000238631 Hexapoda Species 0.000 claims description 2
241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 2
241000244206 Nematoda Species 0.000 claims description 2
241000700584 Simplexvirus Species 0.000 claims description 2
241000700618 Vaccinia virus Species 0.000 claims description 2
230000001580 bacterial effect Effects 0.000 claims description 2
230000002538 fungal effect Effects 0.000 claims description 2
241000701161 unidentified adenovirus Species 0.000 claims description 2
241000701447 unidentified baculovirus Species 0.000 claims description 2
125000003275 alpha amino acid group Chemical group 0.000 claims 4
230000033228 biological regulation Effects 0.000 claims 1
239000013600 plasmid vector Substances 0.000 claims 1
102220166143 rs139444835 Human genes 0.000 claims 1
230000012743 protein tagging Effects 0.000 abstract description 4
150000001413 amino acids Chemical class 0.000 description 24
108090000623 proteins and genes Proteins 0.000 description 14
235000001014 amino acid Nutrition 0.000 description 13
230000014509 gene expression Effects 0.000 description 10
108091028043 Nucleic acid sequence Proteins 0.000 description 9
102000011727 Caspases Human genes 0.000 description 8
108010076667 Caspases Proteins 0.000 description 8
108020004414 DNA Proteins 0.000 description 8
230000027455 binding Effects 0.000 description 8
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 8
230000035772 mutation Effects 0.000 description 8
235000018102 proteins Nutrition 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
230000004807 localization Effects 0.000 description 7
230000030833 cell death Effects 0.000 description 6
230000004913 activation Effects 0.000 description 5
230000005284 excitation Effects 0.000 description 5
108091008146 restriction endonucleases Proteins 0.000 description 5
230000001640 apoptogenic effect Effects 0.000 description 4
238000000684 flow cytometry Methods 0.000 description 4
239000013612 plasmid Substances 0.000 description 4
238000001890 transfection Methods 0.000 description 4
108010062544 Apoptotic Protease-Activating Factor 1 Proteins 0.000 description 3
102100034524 Apoptotic protease-activating factor 1 Human genes 0.000 description 3
102000004039 Caspase-9 Human genes 0.000 description 3
108090000566 Caspase-9 Proteins 0.000 description 3
108020004705 Codon Proteins 0.000 description 3
241000283073 Equus caballus Species 0.000 description 3
239000000975 dye Substances 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
230000003993 interaction Effects 0.000 description 3
239000003550 marker Substances 0.000 description 3
230000002438 mitochondrial effect Effects 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
238000012216 screening Methods 0.000 description 3
239000000725 suspension Substances 0.000 description 3
241000243290 Aequorea Species 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
229930193140 Neomycin Natural products 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
239000004365 Protease Substances 0.000 description 2
102000018779 Replication Protein C Human genes 0.000 description 2
108010027647 Replication Protein C Proteins 0.000 description 2
108091005971 Wild-type GFP Proteins 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
230000007815 allergy Effects 0.000 description 2
239000003124 biologic agent Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000008045 co-localization Effects 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000001514 detection method Methods 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000013537 high throughput screening Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
238000002372 labelling Methods 0.000 description 2
238000004020 luminiscence type Methods 0.000 description 2
239000002609 medium Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
238000001000 micrograph Methods 0.000 description 2
230000017074 necrotic cell death Effects 0.000 description 2
229960004927 neomycin Drugs 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
238000003757 reverse transcription PCR Methods 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
241000894007 species Species 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
238000010186 staining Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
241000242764 Aequorea victoria Species 0.000 description 1
108010089941 Apoptosomes Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
108091006149 Electron carriers Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
101000726354 Equus caballus Cytochrome c Proteins 0.000 description 1
241000233866 Fungi Species 0.000 description 1
102220566469 GDNF family receptor alpha-1_S65T_mutation Human genes 0.000 description 1
108091005973 GFP derivatives Proteins 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
102000007999 Nuclear Proteins Human genes 0.000 description 1
108010089610 Nuclear Proteins Proteins 0.000 description 1
102000007399 Nuclear hormone receptor Human genes 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
102000029797 Prion Human genes 0.000 description 1
108091000054 Prion Proteins 0.000 description 1
241000242743 Renilla reniformis Species 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
241000242583 Scyphozoa Species 0.000 description 1
102220503212 Thioredoxin_K72A_mutation Human genes 0.000 description 1
101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
208000037919 acquired disease Diseases 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000011319 anticancer therapy Methods 0.000 description 1
238000003782 apoptosis assay Methods 0.000 description 1
239000005441 aurora Substances 0.000 description 1
230000006399 behavior Effects 0.000 description 1
238000002306 biochemical method Methods 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000003185 calcium uptake Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000013377 clone selection method Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000010226 confocal imaging Methods 0.000 description 1
230000008602 contraction Effects 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
108091007930 cytoplasmic receptors Proteins 0.000 description 1
210000000172 cytosol Anatomy 0.000 description 1
238000010586 diagram Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000005670 electromagnetic radiation Effects 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000000799 fluorescence microscopy Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
230000005251 gamma ray Effects 0.000 description 1
210000000777 hematopoietic system Anatomy 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000006698 induction Effects 0.000 description 1
150000002484 inorganic compounds Chemical class 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000036244 malformation Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000010198 maturation time Effects 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
IKEOZQLIVHGQLJ-UHFFFAOYSA-M mitoTracker Red Chemical compound [Cl-].C1=CC(CCl)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 IKEOZQLIVHGQLJ-UHFFFAOYSA-M 0.000 description 1
230000027829 mitochondrial depolarization Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
230000004660 morphological change Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
230000007918 pathogenicity Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
208000028591 pheochromocytoma Diseases 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000005522 programmed cell death Effects 0.000 description 1
238000001498 protein fragment complementation assay Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
125000006853 reporter group Chemical group 0.000 description 1
230000004202 respiratory function Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
230000011664 signaling Effects 0.000 description 1
230000007781 signaling event Effects 0.000 description 1
230000003007 single stranded DNA break Effects 0.000 description 1
239000004289 sodium hydrogen sulphite Substances 0.000 description 1
230000010473 stable expression Effects 0.000 description 1
HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000008685 targeting Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000003146 transient transfection Methods 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
238000012795 verification Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/80—Cytochromes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

JP2006544552A 2003-12-19 2004-12-17 シトクロムｃタンパク質及びアッセイ Expired - Fee Related JP4981453B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0329353.7		2003-12-19
GBGB0329353.7A GB0329353D0 (en)	2003-12-19	2003-12-19	Cytochrome C protein and assay
PCT/GB2004/005317 WO2005058960A1 (en)	2003-12-19	2004-12-17	Cytochrome c protein and assay

Publications (2)

Publication Number	Publication Date
JP2008502316A JP2008502316A (ja)	2008-01-31
JP4981453B2 true JP4981453B2 (ja)	2012-07-18

Family

ID=30471316

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2006544552A Expired - Fee Related JP4981453B2 (ja)	2003-12-19	2004-12-17	シトクロムｃタンパク質及びアッセイ

Country Status (9)

Country	Link
US (1)	US8076148B2 (de)
EP (1)	EP1716177B1 (de)
JP (1)	JP4981453B2 (de)
AT (1)	ATE458005T1 (de)
AU (1)	AU2004299336B2 (de)
CA (1)	CA2549523A1 (de)
DE (1)	DE602004025625D1 (de)
GB (1)	GB0329353D0 (de)
WO (1)	WO2005058960A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ541666A (en) *	2005-08-05	2008-09-26	Elizabeth Cramer	Methods of modulating apoptosis and platelet production using an isolated oligonucleotide, its compliment, a vector with the expression sequence or an isolated polypeptide all relating to cytochrome C
FR2926985B1 (fr) *	2008-02-06	2010-05-21	Oreal	Association d'un rayonnement lumineux et d'un substrat de la cytochrome c oxydase pour ameliorer notamment l'apparence de la peau et/ou du cheveu
CN111727044A (zh)	2018-02-05	2020-09-29	深圳市原力生命科学有限公司	用于治疗癌症或炎性疾病的杂二环羧酸

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE184613T1 (de)	1995-09-22	1999-10-15	Novo Nordisk As	Varianten des grünen fluoreszenzproteins, gfp
CA2196496A1 (en)	1997-01-31	1998-07-31	Stephen William Watson Michnick	Protein fragment complementation assay for the detection of protein-protein interactions
US6294330B1 (en)	1997-01-31	2001-09-25	Odyssey Pharmaceuticals Inc.	Protein fragment complementation assays for the detection of biological or drug interactions
US6008378A (en)	1997-10-21	1999-12-28	The Regents Of The University Of California	Synthetic molecules that specifically react with target sequences
US6054271A (en)	1997-10-21	2000-04-25	The Regents Of The University Of California	Methods of using synthetic molecules and target sequences
US5932474A (en)	1997-10-21	1999-08-03	The Regents Of The University Of California	Target sequences for synthetic molecules
EP1301786B1 (de)	2000-07-21	2005-11-30	Evotec AG	Verfahren zur detektion der apoptose durch ermittlung von cytochrom c als apoptosespezifischem marker, der durch zelluläre ausschüttungsvorgänge ins extrazelluläre medium abgegeben wird
GB0109858D0 (en)	2001-04-23	2001-06-13	Amersham Pharm Biotech Uk Ltd	Fluorscent proteins
EP1354953A1 (de)	2002-04-17	2003-10-22	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Smac-Peptide zur Verwendung als therapeutische Mittel gegen Krebs und Autoimmunerkrankungen

2003
- 2003-12-19 GB GBGB0329353.7A patent/GB0329353D0/en not_active Ceased
2004
- 2004-12-17 DE DE602004025625T patent/DE602004025625D1/de not_active Expired - Lifetime
- 2004-12-17 JP JP2006544552A patent/JP4981453B2/ja not_active Expired - Fee Related
- 2004-12-17 WO PCT/GB2004/005317 patent/WO2005058960A1/en not_active Ceased
- 2004-12-17 CA CA002549523A patent/CA2549523A1/en not_active Abandoned
- 2004-12-17 EP EP04806121A patent/EP1716177B1/de not_active Expired - Lifetime
- 2004-12-17 US US10/583,591 patent/US8076148B2/en not_active Expired - Fee Related
- 2004-12-17 AT AT04806121T patent/ATE458005T1/de not_active IP Right Cessation
- 2004-12-17 AU AU2004299336A patent/AU2004299336B2/en not_active Ceased

Also Published As

Publication number	Publication date
WO2005058960A1 (en)	2005-06-30
CA2549523A1 (en)	2005-06-30
US20090053748A1 (en)	2009-02-26
AU2004299336A1 (en)	2005-06-30
EP1716177B1 (de)	2010-02-17
AU2004299336B2 (en)	2008-04-24
GB0329353D0 (en)	2004-01-21
EP1716177A1 (de)	2006-11-02
JP2008502316A (ja)	2008-01-31
ATE458005T1 (de)	2010-03-15
US8076148B2 (en)	2011-12-13
DE602004025625D1 (en)	2010-04-01

Legal Events

Date	Code	Title	Description
2007-12-18	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071217
2010-10-13	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101012
2011-01-12	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110111
2011-01-12	RD02	Notification of acceptance of power of attorney	Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20110111
2011-01-12	RD04	Notification of resignation of power of attorney	Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20110111
2011-01-19	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110118
2011-04-13	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110412
2011-08-31	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110830
2011-12-29	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111228
2012-02-21	A911	Transfer to examiner for re-examination before appeal (zenchi)	Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120220
2012-03-15	TRDD	Decision of grant or rejection written
2012-03-22	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120321
2012-03-29	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01
2012-04-26	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120420
2012-04-27	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20150427 Year of fee payment: 3
2012-04-27	R150	Certificate of patent or registration of utility model	Free format text: JAPANESE INTERMEDIATE CODE: R150
2015-04-27	LAPS	Cancellation because of no payment of annual fees

Publication	Publication Date	Title
JP5988101B2 (ja)	2016-09-07	酸化ストレスインジケーター発現用核酸構築物とその使用
CN111212913A (zh)	2020-05-29	多重测定
JPWO2017094885A1 (ja)	2018-09-20	リガンド蛍光センサータンパク質とその使用
JP3978139B2 (ja)	2007-09-19	Ｒｅｎｉｌｌａｍｕｌｌｅｒｉの緑色蛍光タンパク質をコードするヒト化ポリヌクレオチド配列
JP5954728B2 (ja)	2016-07-20	蛋白質の分解活性を測定するためのプローブ試薬
KR100648761B1 (ko)	2006-11-23	저산소증-유도성 인자 1α ＨＩＦ-1α 변이체 및ＨＩＦ-1α 조절제의 동정 방법
WO2013151511A1 (en)	2013-10-10	Modified Dual-Colour Protein
JP4981453B2 (ja)	2012-07-18	シトクロムｃタンパク質及びアッセイ
KR102074590B1 (ko)	2020-02-06	자가포식체 탐침용 프로브 및 이를 이용한 탐침 방법
Janczyk et al.	2023	Aurora A phosphorylates Ndel1 to reduce the levels of Mad1 and NuMA at spindle poles
US20040171005A1 (en)	2004-09-02	Codon-optimised nucleic acid coding for apoaequorin and uses thereof
EP1674478A1 (de)	2006-06-28	Fusionsproteine und Verfahren zum Nachweis von Protein-Protein Interaktionen in lebenden Zellen und Zellysaten, Nukleinsäuren kodierend für diese Fusionsproteine, sowie Vektoren und Kits, die diese enthalten
KR100997129B1 (ko)	2010-11-29	유전자의 고속 기능분석을 위한 붉은형광단백질 융합단백질 생산용 벡터
US20240011070A1 (en)	2024-01-11	Methods and compositions for protease reporter assays and modulators
CN121335986A (zh)	2026-01-13	R环感测器
Yang et al.	2026	A Sensitive Green-Red FRET Sensor for Calpain-1 Utilizing Heterodimeric Fluorescent Proteins from Distinct Evolutionary Origins
WO2016038750A1 (ja)	2016-03-17	分割型組換えルシフェラーゼ及びそれを用いた解析方法
CN116194468A (zh)	2023-05-30	预测和操纵nmda受体介导的毒性的新手段
WO2007102507A1 (ja)	2007-09-13	タンパク質リン酸化インディケーター
WO2020090668A1 (ja)	2020-05-07	細胞の糖取り込みを可視化するためのキメラタンパク質
Frazier	0	Dnaconda’s Recommendation
Herzig Jr	1999	NRF-1 regulation of respiratory function: Involvement of phosphorylation and protein-protein interactions
Laughery	2006	Cellular localization and assembly of the Na, K-ATPase
Zou	2012	Using Aureochrome to Control Protein-Protein Interactions with Light
KR20070048386A (ko)	2007-05-09	ｐ53 종양 억제단백질과 형광단백질의 융합단백질을발현하는 형질전환 세포주 및 이를 이용한 ｐ53 종양억제단백질의 활성과 관련된 물질의 검색방법